Login
$SGP
$31.67 -$1.21 (3.68%) Live

$SGP SEC Filings

Filed On Filing
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition; Other Events

IRVINE, Calif., Nov. 11, 2026 – SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the third quarter ended Sep...

19 Oct 2026 8-K: Other Events

IRVINE, Calif., October 19, 2026 – SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditi...

01 Oct 2026 8-K: Regulation FD Disclosure; Other Events

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

IRVINE, Calif., Aug. 6, 2026 – SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the second quarter ended Jun...

14 May 2026 10-Q
14 May 2026 8-K: Results of Operations and Financial Condition

ALISO VIEJO, Calif., May 14, 2026 – SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the first quarter ended...

26 Mar 2026 10-K
26 Mar 2026 8-K: Results of Operations and Financial Condition

ALISO VIEJO, Calif., March 26, 2026 – SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the fourth quarter an...

09 Mar 2026 8-K: Other Events

ALISO VIEJO, Calif., March 9, 2026 – SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate,...

17 Feb 2026 SCHEDULE 13G
17 Feb 2026 SCHEDULE 13D
13 Feb 2026 SCHEDULE 13D
13 Feb 2026 SCHEDULE 13D
13 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation

On January 16, 2026, SpyGlass Pharma, Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-292779) with the Securities and Exchange Commission (as amended, the “Registration Statement”). Pursuant to Instruction 1...

13 Feb 2026 SCHEDULE 13G
11 Feb 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 4 others

Received 4,331,117 shares by conversion · Bought 3,690,000 shares ($59M)

11 Feb 2026 Form 4/A: Nielsen Kirk G., Director

Converted 1,690,230 Series B Preferred Stock · Converted 548,067 Series C-1 Preferred Stock · Converted 548,067 Series C-2 Preferred Stock · 1 more

11 Feb 2026 Form 4: Behbahani Ali, Director

Received 6,454,801 shares by conversion · Bought 937,500 shares ($15M)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support